sonelokimab

Home
Ligands
sonelokimab

GtoPdb Ligand ID: 10491

Synonyms: IL17-MS3086 | IL17MS3086 | SEQ ID 836 [WO2012156219A1]

Comment: Sonelokimab (IL17MS3086) is an anti-IL-17A/F single chain camelid nanobody [1]. The peptide sequence for proposed INN sonelokimab is a 100% match for SEQ ID 836 that is claimed in Merck/Ablynx patent WO2012156219A1. IL17MS3086 potently binds to both IL-17A and -F and prevents IL-17R pathway activation (e.g . IL-6 production), and was designed for anti-inflammatory potential. We provide the IL17MS3086 to sonelokimab association in good faith, and await formal disclosure.

Summary
Biological activity
References
Immunopharmacology

Immunopharmacology Comments
IL17MS3086 inhibits IL-6 production in response to both IL-17A and IL-17F in cell-based assays (HT-1080 human fibrosarcoma cells). In vivo efficay has been demonstrated in a collagen-induced cynomolgus monkey arthritis model, and compared to the effects of anti-IL-6 mAb tocilizumab in the same model as a positive control.

Immunopharmacology Comments

IL17MS3086 inhibits IL-6 production in response to both IL-17A and IL-17F in cell-based assays (HT-1080 human fibrosarcoma cells). In vivo efficay has been demonstrated in a collagen-induced cynomolgus monkey arthritis model, and compared to the effects of anti-IL-6 mAb tocilizumab in the same model as a positive control.